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ABSTRACT
Activation-induced deaminase (AID) initiates anti-
body diversification in germinal center B cells by
deaminating cytosines, leading to somatic hyper-
mutation and class-switch recombination. Loss-of-
function mutations in AID lead to hyper-IgM syn-
drome type 2 (HIGM2), a rare human primary anti-
body deficiency. AID-mediated deamination has been
proposed as leading to active demethylation of 5-
methycytosines in the DNA, although evidence both
supports and casts doubt on such a role. In this
study, using whole-genome bisulfite sequencing of
HIGM2 B cells, we investigated direct AID involve-
ment in active DNA demethylation. HIGM2 naı̈ve and
memory B cells both display widespread DNA methy-
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lation alterations, of which ∼25% are attributable to
active DNA demethylation. For genes that undergo
active demethylation that is impaired in HIGM2 in-
dividuals, our analysis indicates that AID is not di-
rectly involved. We demonstrate that the widespread
alterations in the DNA methylation and expression
profiles of HIGM2 naı̈ve B cells result from prema-
ture overstimulation of the B-cell receptor prior to
the germinal center reaction. Our data support a role
for AID in B cell central tolerance in preventing the
expansion of autoreactive cell clones, affecting the
correct establishment of DNA methylation patterns.
INTRODUCTION
Hyper-IgM syndrome type 2 (HIGM2) is a rare primary
antibody deficiency, with autosomal recessive inheritance,
characterized by loss-of-function mutations in activation-
induced deaminase (AID) (1), an enzyme required for sev-
eral crucial steps of B cell terminal differentiation. AID con-
verts deoxycytosines (dCs) into deoxyuracils (dUs), produc-
ing dU:dG mismatches that are removed by mismatch re-
pair and base-excision repair (2). Deaminase activity is re-
quired for somatic hypermutation (SHM) and class-switch
recombination (CSR) of immunoglobulin (Ig) genes, which
are necessary processes for affinity maturation and antibody
diversification within the germinal centers (GC) (3,4). AID
deficiency results in the absence of CSR and SHM, and
leads to lymphoid hyperplasia (1). HIGM2 patients have
normal or elevated serum IgM levels with severe reduction
of IgG, IgA and IgE, resulting in considerable susceptibility
to bacterial infections (1).
In addition to its role in CSR and SHM, AID has
been proposed to participate in active DNA demethylation
through deamination of 5-methylcytosine (5mC), leading
to a mismatch that is converted to G:C by thymine DNA
glycosylase (TDG), followed by base-excision repair. The
potential role of AID in active DNA demethylation was
first proposed by Petersen-Mahrt and colleagues (5). Initial
studies in this topic mainly focusing on non-lymphoid cells,
such as including zebrafish embryos and heterokaryon-
based reprogramming, supported that model (6–8). These
studies subsequently led to its study in B cells, given that
activated B cells display the highest levels of AID expres-
sion (9). During the past decade, conflicting reports have
both supported and discounted a role in active demethyla-
tion for AID in that context [reviewed in (10)]. For instance,
Fritz et al. (11) performed reduced-representation bisulfite
sequencing (RRBS) of mouse splenic naı̈ve B cells from wild
type and AID-deficient mice, activated ex vivo for 72 h and
found no significant differences in their DNA methylation
profiles. Similar conclusions were obtained looking at GC
B cells from AID-deficient mice and using MethylCap-Seq
(12). However, more recently, Dominguez and colleagues
showed that the transit of B cells through the GC is asso-
ciated with marked locus-specific loss of methylation and
increased methylation diversity, both of which are lost in
Aicda−/− animals (13). Methodological aspects could ex-
plain the discrepancies between these studies, including the
limited coverage and resolution of the three aforementioned
analyses, or the study of different cells (in vitro activated or
isolated GC B cells).
On the other hand, different in vitro studies suggest
that 5mC is a poorer substrate than C, although early
studies showed that human AID can deaminate 5mC (5).
For instance, Abdouni and colleagues showed that the ef-
ficient deamination of 5mC by zebrafish AID is due to
the flexibility of its structure, in comparison with that of
other AID orthologs, including human AID (14). In ad-
dition, the comparison of AID with other members of
the AID/APOBEC family have shown that human AID
deaminates 5mC only weakly because the 5-methyl group
fits poorly in its DNA-binding pocket (15). Larijani et al.
have shown that methylated-CpG motifs, but not their un-
methylated counterparts, are in fact protected from AID-
mediated deamination (16). Nabel and colleagues have also
shown that steric requirements for cytosine deamination are
one intrinsic barrier to the proposed function of deaminases
in DNA demethylation (17).
In parallel, the discovery of alternative enzymatic path-
ways that lead to bona fide active DNA demethylation
through ten-eleven translocation methylcytosine dioxyge-
nase (TET)-mediated oxidation of methylcytosines (18,19)
raised more doubts about the possibility that AID redun-
dantly plays such a role. There is currently no consensus
about whether AID is involved in mediating DNA demethy-
lation in specific cell contexts.
Whole-genome analysis has shown the occurrence of a
vast amount of demethylation associated with B cell differ-
entiation. Changes occur mostly during naı̈ve B cell activa-
tion, yielding memory B cells (20,21) that coincide with the
highest peak of AID expression (3). Naı̈ve B cells start to
proliferate upon activation by antigen encounter. Then they
express AID which triggers the secondary diversification of
antibodies by SHM and CSR. This is followed by affinity
maturation which finally leads to (a) a new cycle of SHM or
(b) terminal differentiation into memory or plasma B cells
depending on the affinity of the B cell receptor (BCR) for
the cognate antigen (22). It has been originally reported that
AID is targeted to Ig genes with the involvement of RNA
polymerase II (23). Nevertheless, it has since been described
that AID is also recruited to non-Ig genes to mediate recur-
rent mutations and these genes are collectively termed ‘AID
off-targets’ (24,25).
In this study, we took advantage of the exceptional possi-
bility to investigate the direct role of AID in active demethy-
lation by comparing the complete DNA methylomes of
naı̈ve and memory B cells of HIGM2 patients with those of
healthy individuals. By studying two sibling patients with
a homozygous mutation for AID that results in a severely
truncated enzyme, we were able to determine its direct link
with DNA methylation defects and infer its catalytic activ-
ity in relation to active DNA demethylation.
Our results show that the absence of AID catalytic ac-
tivity affects DNA methylation in naı̈ve and memory B
cells. The majority of the changes occurring in the transition
from naı̈ve to memory B cells arise from passive demethy-
lation and are linked to late-replicating domains. How-
ever, for those potentially associated with active demethy-
lation, we found no evidence of direct involvement of AID,
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ble for DNA methylation changes in this cell context. The
increased DNA demethylation noted in naı̈ve B cells of
HIGM2 patients is associated with premature demethyla-
tion of BCR downstream genes prior to the GC reaction.
Indeed, we found that these changes are related to the ex-
pansion of autoreactive clones, which suggests a major role




The patients included in the study fulfilled the diagnostic
criteria for hyper-IgM syndrome type 2, based on ESID
clinical diagnostic criteria (26) and genetic confirmation of
AICDA mutation and exclusion of other primary and sec-
ondary causes of immunodeficiencies. Samples come from
the Medical Center of the University Hospital, University
of Freiburg, Freiburg, Germany and Hospital Universitari
Vall d’Hebron, Barcelona, Spain. The Committees for Hu-
man Subjects of the local hospitals approved the study,
which was conducted in accordance with the ethical guide-
lines of the 1975 Declaration of Helsinki. All samples were
in compliance with the guidelines approved by the local
ethics committee and all donors (and/or their parents) re-
ceived oral and written information about the possibility
that their blood would be used for research purposes.
Isolation of B cell populations. Peripheral blood mononu-
clear cells (PBMCs) were obtained from blood. After Ficoll-
Isopaque density centrifugation (Rafer, Zaragoza, Spain),
collected cells were washed twice with ice-cold PBS, fol-
lowed by centrifugation at 2000 rpm for 5 min. Next, cells
were labeled with antibodies to CD19 – FITC (Miltenyi
Biotec, clone LT19), CD27 – APC (Miltenyi Biotec, clone
M-T271), IgD – PE (SouthernBiotech, Cat. No. 2032-09)
and IgM – PerCP/Cy5.5 (BioLegend, clone MHM-88) for
20 min on ice in a staining buffer (PBS with 4% FBS and
2 mM EDTA). Naı̈ve B cells (CD19+ CD27– IgD+) and
unswitched memory B cells (CD19+ CD27+ IgD+) were
obtained by FACS sorting on a MoFlo Astrios (Beck-
man Coulter). Purified samples were pelleted and stored at
−80◦C.
For isolation of naı̈ve autoreactive B cells. Total B cells
were isolated from PBMCs using positive selection with
MACS CD19 microbeads (Miltenyi Biotec). Next, cells
were stained with CD27-APC (Miltenyi Biotec, clone M-
T271), IgD – PE (SouthernBiotech, Cat. No. 2032-09),
HLA-DR – PE-Cy7 (eBioscience, clone LN3), 9g4 primary
ab (igm Bioscience) and donkey anti-rat IgG (H + L) –
Alexa Fluor 488 (invitrogen). 9g4+ naı̈ve B cells (CD27–
IgD+ 9g4+) and 9g4- naı̈ve B cells (CD27– IgD+ 9g4–) were
obtained by FACS sorting on a BD FACSAria II (BD
Biosciences). Purified samples were pelleted and stored at
−80◦C.
Genomic DNA extraction. For whole-genome bisulfite se-
quencing, DNA was extracted with a QIAamp DNA mi-
cro kit (Qiagen) according to the manufacturer’s protocol.
For pyrosequencing analysis (detailed below), DNA was
extracted with a Maxwell RSC Cultured Cells DNA kit
(Promega), following the manufacturer’s protocol.
Tagmentation-based whole-genome bisulfite sequencing.
For whole-genome bisulfite sequencing, 30 ng of genomic
DNA was used to produce four independent barcoded
sequencing libraries per DNA sample using the tagmen-
tation method (27). Sequencing of the TWGBS libraries
was done on a HiSeq 2000, PE 125 bp mode. Bisulfite
sequencing reads were processed by the DKFZ bisul-
fite analysis workflow. In brief, the reads were trimmed
using Trimmomatic, pre-processed and aligned using
MethylCTools, with default parameters (V. Hovestadt, S.
Picelli, B. Radlwimmer, M.Z. and P.L., unpublished data),
which uses the Burrows-Wheeler alignment algorithm (28).
Following quality control of bisulfite conversion (>99.5%
in all samples) and of read-mapping (80–90% could be
mapped on average), we performed methylation calling
using methylCtools. A summary of the sequencing data for
each sample is provided in Supplementary Table S1.
Differentially methylated region (DMR) calling. DMRs
were detected with the DeNovoDMR algorithm included
in the Specific Methylation Analysis and Report Tool
(SMART2) (29) using all the default parameters except for
the number of CpGs per segment, which was set to 4, the
absolute mean methylation difference, which was set to 0.2,
and a threshold value of P of 0.01. Only those CpGs with
a coverage of ≥5 in all samples were considered in the
construct of the SMART input matrix. DMR calling was
performed on all possible comparisons between naı̈ve and
memory B cells for both control and HIGM2 patients.
Bisulfite pyrosequencing. 500 ng of genomic DNA was
converted with an EZ DNA Methylation-Gold kit (Zymo
Research), following the manufacturer’s instructions.
Bisulfite-treated DNA was PCR amplified using primers
(see Supplementary Table S2) designed with PyroMark As-
say Design 2.0 software (Qiagen). Finally, PCR amplicons
were pyrosequenced with the PyroMark Q24 system and
analyzed with PyroMark CpG software (Qiagen).
Processing of chromatin immunoprecipitation (ChIP) assays
with sequencing (ChIP-Seq) datasets
Sequencing reads from ChIP-seq experiments from the
BLUEPRINT consortium (21) were mapped to the hg19 as-
sembly of human reference genome using Burrows-Wheeler
Aligner (BWA) v0.7.13 (with parameters -q 5, -l 32, -k
2). After removing reads with MAPQ <30 with Sequence
Alignment/Map (SAMtools) v1.2, PCR duplicates were
eliminated using the Picard function available in MarkDu-
plicates software v1.126. Peak calling was performed us-
ing macs2 (with parameters -p 1e-2 –nomodel –shift 0 -
B –SPMR). Only peaks with an overlap of ≥0.5 between
replicates were considered. Histone mark signals around
DMR sets were extracted with the annotatePeaks.pl algo-
rithm available in Hypergeometric Optimization of Motif
EnRichment (HOMER) software v4.10.3 (with parameters:
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Super-enhancer identification. H3K27ac ChIP-seq data
from BLUEPRINT database were used to identify the
super-enhancer regions, as described previously (30) using
Rank-Ordering of Super-Enhancers (ROSE) software. An
enhancer stitching distance of 15 kb was used along with a
2.5 kb transcriptional start site (TSS)-exclusion window.
DNA methylation data analysis. Hierarchical clustering
was carried out based on Pearson correlation distance met-
rics and average linkage criteria. For low-dimensional anal-
ysis, we used the t-distributed stochastic neighbor embed-
ding (t-SNE) method implemented in the Rtsne v0.15 pack-
age.
Transcription factor motifs were enriched for each set of
DMRs using HOMER software v4.10.3. Specifically, we
used findMotifsGenome.pl algorithm (with parameters -
size given -cpg) to search for significant enrichment against
a background sequence adjusted to have similar CpG and
GC contents.
Transcription factor binding analysis was performed in-
terrogating the overlap between the different sets of DMRs
with ChIP-seq data for transcription factors available for
GM12878 lymphoblastoid cell line from the ENCODE
Project (31). The enrichment factor was calculated against
random regions as a background, and P values were calcu-
lated using Fisher’s exact test. Finally, the transcription fac-
tors downstream of the BCR signaling pathway were man-
ually annotated from a curated database (32).
Chromatin states and histone mark enrichments analysis
for NBC, GC B cells and ncsMBC were assessed using a
custom adaptation of the EpiAnnotator R package (33) us-
ing BLUEPRINT data (21). DMRs were converted to hg38
assembly with the liftOver function in the rtracklayer v1.42
R package.
Replication timing data in the GM12878 lymphoblastoid
cell line were obtained from the UW Repli-seq track of the
UCSC Genome Browser. Genomic replication timing val-
ues were binned in deciles where the first decile contained
the regions of latest replication and the last decile the re-
gions of earliest replication. Identified DMRs were then
overlapped to these regions by genomic location.
DMR annotation for genetic context location was
performed using the annotatePeaks.pl algorithm in the
HOMER software v4.10.3. To determine the location rela-
tive to a CpG island (CGI), we used ‘hg19 cpgs’ annotation
in the annotatr v1.8 R package.
GREAT software (34) was used to enrich downstream
pathways and gene ontologies. We used the single nearest
gene option for the association between genomic regions
with genes.
Genes obtained with HOMER annotation software were
used to study correlations between their associated DMRs
and gene expression data from healthy naı̈ve, memory and
GC B cells from BLUEPRINT database, as well as with the
AID off-target genes dataset obtained from Álvarez-Prado
et al. (35).
All statistical analysis (excluding T-WGBS and ChIP-
seq analyses) were done in R v3.5.1. Data distribu-
tions were tested for normality. Normal data were tested
using two-tailed unpaired Student’s t-tests; non-normal
data were analyzed with the appropriate non-parametric
statistical test. Levels of significance are indicated as:
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Non-
significance (P ≥ 0.05) was indicated as ‘ns’.
Public RRBS of B cell activation. Data of EBV and
CD40/IL4 B cell activation were downloaded from the
NCBI Gene Expression Omnibus (GSE49629) (36). Methy-
lation calls from RRBS data were filtered so that only those
CpGs with a minimum of five reads per position in all sam-
ples were retained. Since RRBS genomic coverage is signif-
icantly lower than T-WGBS we only tested the methylation
status of positions common to two datasets.
BCR activation and EBV infection. For naı̈ve B cell acti-
vation and infection experiments, we obtained buffy coats
from anonymous donors through the Catalan Blood and
Tissue Bank (CBTB). The CBTB follows the principles
of the World Medical Association (WMA) Declaration
of Helsinki. Before providing the first blood sample, all
donors received detailed oral and written information and
signed a consent form at the CBTB. PBMCs were isolated
using Ficoll-Paque gradient centrifugation. Total B cells
were isolated from PBMCs using positive selection with
MACS CD19 microbeads (Miltenyi Biotec). Next, cells
were stained with CD27-APC (Miltenyi Biotec, clone M-
T271) and IgD – PE (SouthernBiotech, Cat. No. 2032–09)
and naı̈ve B cells were sorted as CD27–IgD+. For EBV in-
fection, pure naı̈ve B cells were incubated with B95–8 cell
supernatant for 3 h at 37ºC in order to infect them with
EBV, they were harvested after 30 days. For BCR activa-
tion, pure naı̈ve B cells were cultured in RPMI medium
1640 GlutaMAXTM-1 (Gibco, Life Technologies) contain-
ing 20% fetal bovine serum (Gibco, Life Technologies), 1%
sodium pyruvate and 1% Penicillin Streptomycin (Gibco
Thermo Fisher Scientific, MA, USA). Cells were activated
with 10 g/ml anti-IgM (SouthernBiotech), 0.1 g/ml
MEGACD40L® Protein (Enzo) and 50 ng/ml IL21 (Tebu-
bio) for 24 h (ChIP) or 7 days (bisulfite pyrosequencing).
RNA-sequencing. RNA-sequencing libraries from total
mRNA were prepared and purified using Illumina Stranded
mRNA Prep, Ligation kit (Illumina). Sequencing was
performed on a NextSeq500 (Illumina) with a NextSeq
500/550 High Output Kit v2.5 (75 Cycles, Illumina,
20024906) to generate 38-nucleotide paired-end reads at a
read depth of at least 20 million reads per sample.
RNA-seq data analysis. For bioinformatics analyses, raw
sequence reads were initially processed using FastQC
(Babraham Institute, Cambridge, UK) for quality control,
and then adapter sequences and poor quality reads were
removed using TrimGalore that uses Cutadapt for trim-
ming. Quality-filtered reads were then mapped to the hu-
man genome (hg19) using STAR, and only the uniquely
mapped reads were kept. Read counts were calculated using
HTSeq-count. Differentially expressed genes were identi-
fied using R package DESeq2 (fold change ≥ 2 and adjusted
P-value < 0.05). Inference of TF activities from expression
values were calculated using DoRothEA (37). Kyoto En-
cyclopedia of Genes and Genomes (KEGG) database was
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ChIP-PCR. Cell-sorter isolated naı̈ve B cells from healthy
donors were activated as described above for 24 h. 1 × 106
unstimulated and stimulated B cells were crosslinked with
1% methanol-free formaldehyde (Thermo Fisher) for 10
min subjected to 15 min of sonication utilizing Covaris
M220 Focused-ultrasonicator (Covaris, MA, USA). ChIP
experiments were performed using the LowCell# ChIP kit™
protein A, according to manufacturer’s instructions (Di-
agenode, Liege, Belgium). Anti-BATF antibody (#8638)
and corresponding rabbit IgG (#2729) were both obtained
from Cell Signaling. Protein binding was analyzed by real-
time quantitative PCR, and data are represented as a ratio
of the enriched fraction with respect to input. ChIP primers
are shown in Supplementary Table S2.
RESULTS
Study strategy
We obtained peripheral blood from two sibling HIGM2
patients, both with the same homozygous mutation
for the AICDA gene, and two sex-matched healthy
controls. Specifically, the patients carried a deletion
(Exon 2 c.22 40del19) that generates a frameshift vari-
ant (p.Arg8Asnfs*19) that affects the DNA binding re-
gion of AID located within its nuclear localization sig-
nal domain (Figure 1A). This deletion impairs both CSR
and SHM (38). We confirmed the impact on CSR by in-
specting the peripheral B cell compartment by flow cy-
tometry. The two HIGM2 patients were characterized by
the absence of class-switched memory B cells (csMBC;
CD19+CD27+IgM–IgD–), as described (1) (Figure 1B). In
contrast, classic non-class switched memory B cells (nc-
sMBC; CD19+CD27+IgM+IgD+) and naı̈ve B cells (NBC;
CD19+CD27–IgM+IgD+) were present in patients (Figure
1B). It has been shown that, under physiological condi-
tions, ncsMBC cells display certain levels of SHM at the
immunoglobulin locus (20), which supports the expression
of AID during their maturation in GCs. Hence, the com-
parison between DNA methylation profiles of NBC and nc-
sMBC isolated from healthy and HIGM2 individuals is an
adequate model to investigate the potential role of AID in
DNA demethylation.
HIGM2 patients display an aberrant methylation profile in
naı̈ve and unswitched memory B cells
We performed tagmentation-based whole-genome bisulfite
sequencing (T-WGBS), a version of the WGBS method that
allows analysis of limited DNA amounts (27), in NBC and
ncsMBC (henceforth referred to as ‘naı̈ve’ and ‘memory’
B cells) isolated from two HIGM2 siblings and two sex-
matched healthy controls (Figure 1C). Pearson correlation
and t-distribution stochastic neighbor embedding (t-SNE)
between samples were highly reproducible between repli-
cates with correlation coefficient to be >0.9 (Supplementary
Figure S1A, B). We also compared our DNA methylation
data from healthy controls with public data from the In-
ternational Cancer Genome Consortium (ICGC) (39) and
Oakes et al. (20), in which we observed high correlation
(Pearson correlation >0.85), thereby confirming the robust-
ness of our data (Supplementary Figure S1C, D).
Global inspection of DNA methylation confirmed pre-
vious studies (20,21) that the transition from naı̈ve to
memory B cells is accompanied by global demethylation
of the genome in healthy controls (Figure 1D). However,
HIGM2 patients showed a partial impairment of demethy-
lation during naı̈ve-to-memory B cell differentiation (Fig-
ure 1D, E), which is compatible with a potential role of
AID as a demethylating enzyme. The transition from naı̈ve
to memory B cells in healthy controls is characterized by
the demethylation of 30175 DMRs. In contrast, compar-
ing naı̈ve to memory B cells in HIGM2 patients only iden-
tified 4803 hypomethylated DMRs (Supplementary Table
S3). Furthermore, we also observed that naı̈ve B cells were
more demethylated in HIGM2 patients than in healthy con-
trols (a total of 2936 hypomethylated DMRs) (Figure 1F).
Taken together, these global observations suggest that AID
loss not only affects the DNA methylation patterns in the
transition from naı̈ve to memory B cells but also has a po-
tential role in establishing the B cell DNA methylome in ear-
lier stages of development.
A high proportion of DNA demethylation events identified in
HIGM2 are due to passive demethylation of late-replicating
domains
Recent studies have shown that a high proportion of the
demethylation events occurring in cancer and in differenti-
ation processes are associated with high proliferation rates
(40). Such demethylation events take place in regions known
as ‘partially methylated domains’ (PMDs), which are char-
acterized by repressive chromatin and low-GC density (40),
and do not appear to occur in regions of high methylation
(HMD: highly methylated domains). PMDs encompass re-
gions that undergo late replication and their demethyla-
tion is a passive event, which is a result of inefficient DNA
remethylation during DNA replication (36,40,41). Recent
reanalysis of the B cell lineage DNA methylation profiles
published by the BLUEPRINT consortium (21) has shown
the occurrence of demethylation of PMDs in the transi-
tion towards memory B cells and antibody-secreting plasma
cells (42). This highlights the importance of separating
DNA methylation analysis into PMD and non-PMD re-
gions when interrogating the occurrence of active demethy-
lation processes in order to exclude those changes due to
DNA replication-dependent or passive demethylation.
To address this matter, we first identified total dif-
ferentially methylated regions (DMRs) by performing
pairwise comparisons of DNA methylation between all
samples. Specifically, we compared naı̈ve to memory
B cells in both control and HIGM2 patients (con-
trol NBC versus control ncsMBC, HIGM2 NBC versus
HIGM2 ncsMBC), as well as comparing HIGM2 patients
to controls for both naı̈ve and memory B cells (con-
trol NBC versus HIGM2 NBC, control ncsMBC versus
HIGM2 ncsMBC). We then divided the DMRs into PMD
and HMD regions, which were previously identified by
Zhou et al. (40) to be present either in all cell types (com-
mon) or cell-type specific (partial). We found that the major-
ity of DMRs overlapped with PMDs that were either com-
mon or partially shared by cell types (72.5%, Figure 2A).
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DNA binding 13 26 Hotspot recognition loop 113 123 CSR specific173 198
Figure 1. DNA methylomes of HIGM2 B cell subpopulations determined by T-WGBS. (A) Graphical representation of wild type (WT) AICDA gene and
truncated AID of HIGM2 patients used in this study. The mutation in HIGM2 AID harbors a deletion from 22–40 which encompasses the DNA binding
domain. (B) Representative examples of cell sorting strategy of B cell populations (naı̈ve B cells, NBC; classic non-class-switched memory B cells, ncsMBC;
class-switched memory B cells, csMBC). (C) Description of the B cell subpopulations analyzed, including surface markers and details of mutation. (D)
Circos plot of DNA methylation of naı̈ve B cells (inner circle) and unswitched memory B cells (outer circle) for controls (right) and HIGM2 patients
(left). Histogram tracks represent the average methylation levels of 10 Mb windows. Heatmap shows the DNA methylation differences between naı̈ve and
memory B cells (E) Density scatter plots of average DNA methylation in windows of 500 bp in naı̈ve and memory B cells in controls (left) and HIGM2
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Figure 2. Detection and characterization of partially methylated regions. (A) Bar plot showing the percentage of DMRs in PMD and HMD (partially
and highly methylated domains, respectively) regions annotated by Zhou and colleagues (40). ‘Common’ refers to PMD and HMD regions common to all
cell types analyzed by Zhou and colleagues. ‘Partial’ refers to those regions detected only in a fraction of the cell types analyzed. (B) Box and violin plots
summarizing the distribution of DNA methylation levels for controls and HIGM2 patients, in which the DMRs were characterized as inside (PMD-DMRs)
and outside (non-PMD-DMRs) of PMDs. (C) Location proportions of PMD-DMRs and non-PMD-DMRs in the context of CpG islands (CGIs) and
gene-related regions. (D) Bubble chart depicting the enrichment (red) or depletion (blue) of chromatin states defined from ChromHMM ChIP-seq data of
healthy naı̈ve, GC and unswitched memory B cells. Color scale represents the logarithmic fold change, circle size indicates the percentage of DMRs in the
chromatin state, and the edge color indicates the statistical significance of the enrichment (black: significant, none: not significant; q < 0.01). (E) ChIP-seq
data of the represented histone marks in healthy GC B cells were downloaded from the BLUEPRINT database and mean coverage was calculated for
10bp bins ±5 kb centered around the midpoints of PMD-DMRs (left) and non-PMD-DMRs (right). (F) Circular representation of the proportion of
PMD- (outer circle) and non-PMD-DMRs (inner circle) in deciles of replication timing data of GM12878 cell line. Color scale represents the proportion
of DMRs in each decile. The first and last deciles correspond to the regions of latest and earliest replication, respectively. (G) Box and dot plots showing the
distribution of expression values of associated genes of PMD- and non-PMD-DMRs. FPKM refers to fragments per kb of transcript per million mapped
reads. Expression data from healthy GC B cells downloaded from BLUEPRINT database. Statistical tests: two-tailed Fisher’s exact (D) and unpaired
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prising DMRs that coincided with common PMDs (PMD-
DMRs), and the second containing DMRs that did not
overlap with common PMDs (non-PMD-DMRs). To val-
idate the identity of these PMD-DMRs, inspection of the
methylation values showed that the two groups of DMRs
had intermediate methylation values in memory B cells,
although non-PMD-DMRs had slightly lower methyla-
tion levels (Figure 2B). Utilizing functional genomic fea-
ture analysis, we found that most PMD-DMRs were lo-
cated outside of CpG islands and in intergenic regions (Fig-
ure 2C). In relation to chromatin states, we observed that
DMRs occurring in PMDs were mainly associated with het-
erochromatic regions, while non-PMD-DMRs were highly
enriched at enhancers and active promoters, in concor-
dance to what was previously described as generally associ-
ated with replication-independent demethylation (43) (Fig-
ure 2D). This was also confirmed by overlapping DMRs
with ChIP-seq data of healthy GC B cells obtained from
the BLUEPRINT database, in which non-PMD-DMRs
were enriched in enhancer marks, including H3K4me1,
H3K4me3 and H3K27ac (Figure 2E). It has been previ-
ously described that PMDs are characterized by their as-
sociation with late-replication domains (40), hence we ana-
lyzed DMRs based on their association with late or early
phase replication. First, genomic density data obtained
from GM12878 Repli-seq (UW Repli-seq, UCSC Genome
Browser) were divided into deciles by their replication tim-
ing and then overlapped by genomic location with identi-
fied DMRs. We confirmed that PMD-DMRs were mainly
found in late-replicating regions (Figure 2F) and were ac-
companied by lower expression of associated genes in GC
B cells (Figure 2G). Taking all these observations into ac-
count, our results suggest that most of the DNA methyla-
tion changes occur in bona fide PMDs. However, the exis-
tence of a set of non-PMD-DMRs (∼27%) located in highly
active regions suggests the potential participation of DNA
replication-independent or, in other words, active demethy-
lation events, and AID could directly drive these events.
HIGM2-associated defects in DNA methylation in the tran-
sition from naı̈ve to memory B cells do not have the features
of AID targets
Given all the previous considerations, including the removal
of DNA methylation changes related to DNA replication
(PMD-DMRs), our model allows us to examine whether
AID has a direct role in mediating demethylation in the
B cell lineage. In this context, GC B cells, in the transi-
tion from naı̈ve to memory, displayed the highest AICDA
mRNA levels (Supplementary Figure S2A) (as obtained
from the BLUEPRINT database). Hence, it is plausible that
defective AID in HIGM2 patients could play a role in aber-
rant DNA demethylation occurring during the transition
from naı̈ve to memory B cells within the GC.
To explore this possibility, we first identified DMRs
whose DNA demethylation could potentially be driven by
AID (P-AID DMRs). These DMRs are demethylated in the
transition from naı̈ve to memory B cells in healthy controls
but not in HIGM2 patients. Furthermore, DMRs that were
already aberrantly demethylated in naı̈ve HIGM2 B cells
compared to controls were excluded (Figure 3A). A total of
522 DMRs (containing 450 different genes) fulfilled these
conditions (Supplementary Table S4).
We then compared P-AID DMRs associated genes with
data obtained from a mouse model that allows the identifi-
cation of targets of AID deamination events (35), in which
271 non-Ig genes were identified to be dependent on AID
catalytic activity and referred to as AID off-target genes. We
found low correspondence between these two sets of genes
in which only 6 genes (corresponding to 6 DMRs) overlap
with the identified AID off-target genes (Figure 3B). We
also tested for the presence of described AID hotspot se-
quences (RGYW and WRCY) (44) in our DMRs and found
a significant increase for the WRCY hotspot with respect to
the background, although it appeared too low (<1 hotspot
per 100 bp) to be of biological relevance (Figure 3C). On the
other hand, we found that DMRs associated with AID off-
target genes underwent demethylation in HIGM2 patients
(Supplementary Figure S2B).
Two recent studies have characterized the genomic and
epigenomic features of AID off-target regions in mice. Inde-
pendently, they found that AID targets regions with conver-
gent transcription from intragenic super-enhancers (45,46).
In this sense, there were no significant differences regard-
ing gene localization between the DMRs associated with
AID off-targets and P-AID DMRs (Supplementary Fig-
ure S2C and Supplementary Table S4). However, AID off-
target DMRs exhibited greater enrichment of enhancer re-
gions, as observed by both ChromHMM (Figure 3D) and
histone mark (Supplementary Figure S2D) analyses, and
were associated with more transcriptional activity of as-
sociated genes in GC B cells (Figure 3E). We also found
that, although the two DMR groups had a similar percent-
age of overlap with super-enhancers (P-AID 21%, AID off-
target 33.3%; Figure 3F), the super-enhancers of the AID
off-targets had a stronger signal for H3K27ac (Figure 3G,
H; Supplementary Figure S2E) and greater transcriptional
activity of their associated genes than P-AID (Supplemen-
tary Figure S2F). Finally, we hypothesized that if AID had a
role mediating active DNA demethylation, we would expect
to see differences in CpG sites containing WRCY hotspots
at the super-enhancers of AID off-target genes. However,
such differences were not observed (Supplementary Figure
S2G).
Taken together, our results suggest that, despite the differ-
ences in DNA methylation associated with B cell activation
between wild type and AID-deficient B cells, if we assume
that mechanisms and targets are conserved between mouse
and human, such demethylation may not be directly associ-
ated with AID catalytic activity.
While the proposed mechanism of DNA demethyla-
tion by AID implies that the 5mC conversion in thymine
could be repaired and replaced with an unmethylated cy-
tosine (5), the removal of methyl groups of cytosines me-
diated by TET enzymes involves the generation of oxida-
tion intermediates, including 5hmC (18) (Supplementary
Figure S3A). It is therefore plausible that AID-dependent
demethylation would associate with lower levels of 5hmC
compared to TET-dependent demethylation. Hence, we an-
alyzed publicly-available DNA methylation data obtained
from GC and naı̈ve B cells of Aicda–/– mice (13). We selected
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Figure 3. Indirect involvement of AID in DNA demethylation dynamics during B cell activation. (A) Box and violin plot representation of DNA methy-
lation of DMRs that are potentially demethylated directly by AID (P-AID). These DMRs were filtered by the presence of demethylation between control
naı̈ve and memory B cells which were not present in HIGM2 B cells. Furthermore, DMRs that displayed demethylation in HIGM2 naı̈ve B cells compared
to controls were excluded. (B) Venn diagram showing the overlap between associated genes of P-AID DMRs and the human orthologues of mouse AID
off-target genes as defined by Álvarez-Prado et al. (35). (C) Box and violin plots displaying the frequency of WRCY/RGYW (W = A/T; R = G/A; Y
= C/T) hotspots per 100 bp in DMRs of each subset. Background was generated as 100bp windows of the whole genome. (D) Bubble plot depicting the
enrichment (red) or depletion (blue) of chromatin states. Color represents the logarithmic-fold change, size shows the percentage of DMRs in the chromatin
state, and the edge indicates the statistical significance of the enrichment (black: significant, none: not significant, q-value < 0.01). Chromatin state data
was obtained from ChromHMM, generated in GC B cells. (E) Circular representation of proportion of DMRs in deciles of genes whose expression is
ranked from low to high expression in GC B cells. The first and last deciles correspond to the least and most highly expressed genes, respectively. Color
scale represents the proportion of DMRs in each decile. Gene expression data was obtained from the BLUEPRINT database. (F) Venn diagram of the
overlap between P-AID and AID off-target DMRs with super-enhancers in GC B cells. Super-enhancer identification is described in the Materials section
utilizing H3K27ac ChIP-seq data from the BLUEPRINT database. (G) Box plots showing H3K27ac ChIP-seq peaks of super-enhancers associated with
AID off-target (red) and P-AID (green) DMRs. One-sided unpaired Wilcoxon’s test was used to examine signal intensity differences. (H) DNA methylation
and H3K27ac profiles in the vicinity of two representative genes. DMR color indicates the type of DMR, either P-AID (green) or AID off-target DMRs
(red). H3K27ac ChIP-seq signals from GC B cells are shown in dark orange. Super-enhancers and enhancers are depicted. Statistical tests: two-tailed
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from naı̈ve to GC B cells in WT but not in Aicda–/– mice,
termed mouse potential AID targets (mouse P-AID); (ii)
CpGs significantly demethylated in naı̈ve-to-GC transition
in both WT and knockout mice and, therefore, more likely
to be TET-dependent, termed positive control; (iii) CpGs
that did not present demethylation in the transition from
naı̈ve to GC B cells neither in WT nor in Aicda–/– mice,
termed negative control (differential DNA methylation <
0.05) (Supplementary Figure S3B). Next, we merged this
data with public hydroxy-meDIP-seq data of mouse B cell
activation (47) to determine the hydroxymethylation status
of these three groups of CpGs. We found that mouse P-
AID CpGs presented similar levels of hydroxymethylation
to those that are TET-dependent (positive control) com-
pared to negative control (Supplementary Figure S3C). On
the other hand, we only found 21 genes associated with
mouse P-AID CpGs that overlapped with the aforemen-
tioned AID off-target genes (18), which represents <8%
of the AID-off target genes (Supplementary Figure S3D).
Taken together, these results suggest that, at least in a mouse
model, the majority of demethylation associated with B cell
differentiation may not be directly driven by AID activity.
AID deficiency results in premature demethylation of the
BCR pathway of naı̈ve B cells
Our initial analysis suggested that alterations in DNA
methylation not only occurred in the transition from naı̈ve
to memory B cells, but were already present in naı̈ve B cells
of HIGM2 individuals in comparison with healthy con-
trols. Specifically, HIGM2 naı̈ve B cells appeared to be more
demethylated than those of healthy controls (Figures 1F
and 4A). AID expression has customarily been associated
with the GC reaction (3), however, more recent evidence
suggests that AID may have a role in earlier stages of B cell
development (48,49).
Comparing naı̈ve B cells from HIGM2 to control, we de-
tected 2152 hypomethylated DMRs (Figure 4A) and 127
hypermethylated DMRs (Supplementary Figure S4A), ex-
cluding PMDs. Both hypo- and hypermethylated DMRs
were mostly found outside CpG islands in intergenic regions
and introns (Supplementary Figure S4B). Genetic annota-
tion of DMRs in CpG islands reveals an association with
promoters (Supplementary Figure S4C and Supplementary
Table S5). However, while hypomethylation was associated
with enhancer regions, hypermethylation was mainly en-
riched in promoters (Supplementary Figure S4D), in agree-
ment with its reported regulatory role in the ‘spurious’ ini-
tiation of transcription (50).
We observed that the DMRs that were hypomethylated
in naı̈ve B cells from HIGM2 patients underwent normal
demethylation during the transition from naı̈ve to memory
cells in healthy controls (Figure 4A). Our results suggest
that the demethylation of these DMRs may be essential for
correct naı̈ve-to-memory B cell differentiation, and prema-
ture demethylation observed in HIGM2 naı̈ve B cells may
indicate aberrant pre-activation outside of the GC. This is
consistent with the finding that genes associated with these
DMRs became upregulated during the activation of B cells
in the GC (Figure 4B) and were associated with functional
categories related to B cell activation via BCR (Figure 4C).
Some genes that have altered DMRs, such as BATF (Figure
4D) and MEF2A (Supplementary Figure S4E), are crucial
to B cell development (47,51).
To explore the possibility that aberrant DNA methyla-
tion in HIGM2 naı̈ve B cells may be due to pre-activation
outside the GC, we first analyzed the enrichment for TF
binding motifs with HOMER software in HIGM2 naı̈ve
DMRs. Some of the most enriched TFs are downstream
of the BCR pathway, including BATF, IRF8 and RELA
(32) (Supplementary Figure S4F). We then validated these
results through enrichment analysis of the ChIP-seq data
available for GM12878 cells from the ENCODE consor-
tium (31) and we again observed enrichment of TFs down-
stream of BCR activation in DMRs found to be altered in
naı̈ve B cells of HIGM2 patients (Figure 4E).
The type III latency state of the Epstein-Barr virus
(EBV) is characterized by the constitutive activation of
the BCR and CD40 pathways (52,53), both of which
are major signaling pathways essential for B cell activa-
tion (54). In that sense, the B lymphoblastoid cell line
GM12878 presents a type III latency state (55) and is
therefore a good model to investigate the involvement of
BCR/CD40 in aberrant DNA methylation of naı̈ve B cells
in HIGM2 patients. Firstly, we represented DNA methy-
lation levels of publicly-available data of EBV-transformed
and CD40L/IL-4-activated B cells (36) in regions that over-
lapped with DMRs identified in naı̈ve B cells of HIGM2
patients and observed that EBV transformation effectively
reproduced the aberrant DNA demethylation presented in
HIGM2 patients (Figure 4F). Conversely, such changes
did not take place when activation was performed with
CD40/IL-4 alone, suggesting that the BCR pathway has a
significant role in driving aberrant DNA methylation (Fig-
ure 4F). Furthermore, these DNA methylation effects were
not reproduced in hypermethylated DMRs (Supplementary
Figure S5A). To confirm these results, we transformed naı̈ve
B cells isolated from healthy donors with EBV and, after 30
days, we interrogated DNA methylation of the set of CpGs
that we had previously identified to be aberrantly demethy-
lated in HIGM2. We observed that these CpGs underwent
demethylation following EBV-mediated transformation of
naı̈ve B cells (Supplementary Figure S5B). Additionally, we
directly stimulated BCR in isolated healthy naı̈ve B cells and
observed similar demethylation of the same CpGs, which
supported the direct role of BCR in their demethylation
(Figure 4G). Taken together, our findings suggest that al-
terations in DNA methylation of HIGM2 naı̈ve B cells may
at least be partly due to the aberrant pre-activation of the
BCR at some point of B cell development prior to the GC
reaction.
Since ChIP-seq analysis in GM12878 cells identified
BATF to bind to almost 50% of regions that correspond
to DMRs in HIGM2 naı̈ve B cells (Figure 4E), we there-
fore hypothesize that BATF might be the main media-
tor of demethylation in naı̈ve-to-memory transition, and
its aberrant recruitment may drive the aberrant demethy-
lation observed in HIGM2 naı̈ve B cells. BATF, together
with IRF4 (56,57), is a regulator of B and T cell acti-
vation via the BCR and TCR pathways respectively. We
observed that 87% of the ChIP-seq peaks of IRF4 over-
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Figure 4. Role of AID in early B cell development. (A) Box and violin plot representation of DNA methylation of hypomethylated DMRs identified
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pected, we confirmed that regions with BATF and IRF4
binding had lower DNA methylation levels in naı̈ve B cells
of HIGM2 patients compared to controls (Supplementary
Figure S5C). This is also confirmed for regions that con-
tained JUND binding, another TF downstream of BCR
(Supplementary Figure S5D). This did not occur in re-
gions enriched for other B cell-intrinsic TF binding motifs,
such as RAD21, ZNF274 and MYC (Supplementary Fig-
ure S5D). Using mRNA transcription data from IRF4 and
BATF knockouts from GM12878 cells (55), we determined
that genes with binding motifs for both TFs displayed ex-
pression changes for many of these genes associated with
DMRs (Supplementary Figure S5E). Furthermore, we ob-
served that BATF was specifically recruited to genes that
displayed defective DNA demethylation in HIGM2 patients
when naı̈ve B cells were activated via BCR stimulation (Fig-
ure 4I). Altogether, these results suggest that a significant
fraction of DMRs identified in HIGM2 naı̈ve B cells may
be associated with the recruitment of the BATF/IRF4 com-
plex to these genomic sites.
The transcriptome of AID-deficient naı̈ve B cells also reflects
alterations in the BCR pathway
We then inspected whether loss of function of AID had
an impact on the transcriptomic profiles of both naive
and memory B cells. To this end, we performed RNA-
seq of both naı̈ve and memory B cells from the same two
aforementioned HIGM2 patients. In parallel, we performed
RNAseq with two healthy controls.
Comparison of the naı̈ve B cells transcriptomes revealed
statistically significant expression changes of a number of
genes in HIGM2 compared to controls (DEGs: differen-
tially expressed genes). DEGs were considered to be statisti-
cally significant when fold change ≥2 and adjusted P-value
<0.05. 3223 genes became upregulated in HIGM2 naı̈ve B
cells in relation to healthy controls, whereas 3146 genes were
downregulated. (Figure 5A and Supplementary Table S6).
We then performed Gene Ontology analysis of DEGs using
GREAT software which revealed enrichment of categories
related to EBV activation and BCR signaling pathway (Fig-
ure 5B), consistent with our previous findings related to
DNA methylation alterations in naı̈ve B cells of HIGM2.
Interestingly, we also observed differences in gene expres-
sion in memory B cells (2199 upregulated genes, 2384 down-
regulated) (Supplementary Figure S6A and Supplemen-
tary Table S6) which were also enriched in the aforemen-
tioned categories (Supplementary Figure S6B). Utilizing
DoRothEA TF analysis, we observed that DEGs identified
in naı̈ve B cells of HIGM2 patients also displayed increased
TF activity compared to controls (Figure 5C), where sim-
ilar results were observed for memory B cells (Supplemen-
tary Figure S6C). Integration of the DNA methylation and
expression datasets in naı̈ve B cells did not show a clear
correlation when comparing HIGM2 versus controls (Fig-
ure 5D). Interestingly, hypomethylated DMRs in HIGM2
naı̈ve B cells showed slightly increased expression levels in
HIGM2 naı̈ve B cells in respect to control naı̈ve B cells.
The naı̈ve B cell expression levels of hypomethylated DMRs
of HIGM2 patients were more similar to those of memory
B cells, reinforcing the notion of a premature activation of
these cells in HIGM2 (Figure 5E).
AID deficiency causes blockade of central B cell tolerance
with an expansion of pre-activated autoreactive B cells
Our results suggest that naı̈ve B cells are pre-activated in
AID deficient patients. However, the stage of B cell differ-
entiation at which this alteration is produced remains to be
established. Two independent studies reported a potential
role for AID in removing autoreactive B cells during the
central B cell tolerance process in the bone marrow (48,49).
Specifically, immature B cells with auto-reactive BCR were
activated and went into a secondary receptor editing pro-
cess with an increase in AID and recombination-activating
gene 2 (RAG2). If the autoreactive BCR did not lose self-
antigen affinity, the genomic instability induced by the over-
exposure to high levels of AID led to apoptosis. However,
AID deficiency reduces the genomic damage that causes the
expansion of autoreactive B cells (48,49). With that in mind,
we hypothesized that the presence of naı̈ve B cells with a
pre-activation methylation signature in HIGM2 patients is
a consequence of the impairment of the central B cell toler-
ance mechanism that causes autoreactive naı̈ve B cells to ac-
cumulate. In fact, it has been reported that 21% of HIGM2
patients suffer some type of autoimmune disease (58).
To assess this hypothesis, we first checked whether there
is an expansion of naı̈ve autoreactive B cells in HIGM2
patients with respect to controls. To this end, we used a
commercial antibody against 9G4+ IgG used to detect au-
toreactive clones in autoimmune diseases like systemic lu-
pus erythematosus and rheumatoid arthritis (59,60). We ob-
served an expansion of the naı̈ve B cell compartment in
HIGM2 patients in comparison with healthy controls (Fig-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(red) B cells. Gene expression data obtained from BLUEPRINT database. FPKM refers to fragments per kilobase of transcript per million mapped reads.
(C) Results of gene set enrichment analysis using GREAT software. The plot depicts the top five enriched terms for five annotation databases ranked by
P-values from the binominal distribution. All the depicted enriched terms passed a significance threshold of adjusted P-value < 0.05. (D) Smoothed DNA
methylation data of BATF-associated DMRs in HIGM2 naı̈ve B cells and H3K27ac ChIP-seq signal, super-enhancer and enhancer location in GC B cells.
H3K27ac ChIP-seq data obtained from BLUEPRINT database. (E) Bubble scatter plot of transcription factor ChIP-seq peaks determined in GM12878
lymphoblastoid cell line in regions that correspond to DMRs identified in HIGM2 naı̈ve B cells. Transcription factors downstream of BCR signaling are
colored according to the transcription factor family. Bubble size corresponds to the logarithm of adjusted P-values. ChIP-seq data were obtained from
ENCODE consortium (31). FDR refers to false discovery rate. (F) Box and violin plots summarizing the distribution of DNA methylation of regions
that correspond to HIGM2-identified DMRs in resting B cells (Unstimulated), B cells activated with CD40L/IL4 and B cells infected with Epstein-
Barr virus (EBV). Data of resting and activated B cells obtained from Hansen et al. (36) (G) Dot plot showing the DNA methylation values determined by
pyrosequencing of naı̈ve B cells (naı̈ve) and B cells activated with anti-BCR/CD40L/IL-21 (activated) from healthy donors. (H) Venn diagram representing
the overlap between BATF and IRF4 ChIP-seq peaks in the GM12878 cell line. (I) Dot and bar plot representation of BATF ChIP-qPCR results of naı̈ve
B cells (naı̈ve) and naı̈ve B cells activated with anti-BCR/CD40L/IL-21 (activated) from healthy donors. Statistical tests: Student’s t-test (G, I) (* P-value
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Figure 5. RNA sequencing analysis of naı̈ve B cells transcriptomes from HIGM2 patients and healthy donors. (A) Volcano plot representation of the
transcriptomic comparison of HIGM2 with control naı̈ve B cells. In blue, genes that are differentially expressed (absolute of fold change ≥2 and adjusted
P-value < 0.05). (B) Gene Ontology analysis representation of differentially expressed genes. All represented categories are statistically significantly enriched
(adjusted P-value < 0.05). Gene ratio refers to the ratio between the unique genes present in the DMRs that are associated with a Gene Ontology term
and all the genes potentially included in that ontology gene set. Dot size represents the number of times each term is represented in the DMRs. Dot
color represents adjusted P-value. (C) Heatmap representation showing TF activity predicted using DoRothEA from mRNA expression of differentially
expressed genes in control and HIGM2 naı̈ve B cells. Color represents normalized enrichment scores (NES) where blue and red represent a decreased and
increased activity, respectively, in comparison to background. (D) Correlation between DNA methylation differences and gene expression scaled counts
ratio in naı̈ve B cells from HIGM2 and controls. Colors represent genetic context location. (E) Box and violin plot representation of expression values per
sample group from the genes associated with hypomethylated DMRs in HIGM2 naı̈ve B cells. Statistical tests: Spearman’s rank correlation test (D) and
two-tailed unpaired Wilcoxon’s (E) (ns is non significant).
ure 6A, B). We did not find an expansion of 9G4+ cells in
HIGM2 patients with respect to controls (Figure 6C). How-
ever, we observed a significant increase of mean fluorescence
intensity for 9g4 staining (Figure 6A, D), as well as, an ex-
pansion of high 9g4+ naı̈ve B cells (Figure 6E). Next, we
determined the methylation status of a selection of genes
by pyrosequencing of 9G4– (non-autoreactive) and 9G4+
(autoreactive) naı̈ve B cells and found that autoreactive B
cells had lower levels of DNA methylation than their non-
autoreactive counterparts (Figure 6F). Overall, our results
suggest that the demethylation in naı̈ve B cells of HIGM2
patients compared with control donors is associated with
an expansion of pre-activated autoreactive naı̈ve B cells as
a consequence of central B cell tolerance impairment medi-
ated by AID deficiency.
DISCUSSION
Our results show that AID deficiency in HIGM2 syndrome
results in the acquisition of aberrant DNA methylation
profiles in naı̈ve and memory B cells. First, we observed
the presence of HIGM2-associated DNA methylation al-
terations occurring in the transition from naı̈ve to memory
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Figure 6. Central B cell tolerance impairment by AID deficiency. (A) Representative example of strategy for sorting naı̈ve autoreactive B cells. (B) Dot plot
showing the percentage of naı̈ve B cells in the B cell compartment of HIGM2 patients and controls. (C) Dot plot showing the percentage of autoreactive
naı̈ve B cells in the naı̈ve B cell compartment of HIGM2 patients and controls. (D) Dot plot showing the mean fluorescence of 9g4+ gate. (E) Dot plot
showing the percentage of high 9g4+ naı̈ve B cells in the naı̈ve B cell compartment of HIGM2 patients and controls. (F) Dot plot showing the DNA
methylation values determined by pyrosequencing of control naı̈ve B cells (naı̈ve), HIGM2 patient 9g4– naı̈ve B cells (9g4–) and HIGM2 patient 9g4+
naı̈ve B cells (9g4+). Statistical tests: student t-test (* P-value < 0.05, ns is not significant).
mediated mechanisms. Second, compared to AID mouse
models, we observed that AID may not be directly involved
in the small proportion of those DNA methylation alter-
ations attributable to active demethylation. Third, the com-
parison of naı̈ve B cells in HIGM2 and healthy controls
showed premature demethylation of genes downstream of
the BCR in AID-deficient individuals, which was associated
with the expansion of autoreactive B cell clones prior to the
GC reaction. This reinforces a novel role for AID in pre-
venting the expansion of autoreactive B cell clones, affect-
ing the DNA methylation profiles of naı̈ve B cells.
Our study indicates that AID does not play a direct role in
mediating active demethylation in the transition from naı̈ve
to memory B cells. This transition is associated with the
highest proportion of DNA methylation changes of the en-
tire B cell differentiation process (20,21) and also coincides
with the highest peak of AID expression. Previous studies
addressing the potential participation of AID in demethy-
lation had not considered late-replicating domains or the
relationship between DNA methylation changes and the
genomic features of AID targets. In our study, we deter-
mined that most of the changes taking place during the
transition from naı̈ve to memory B cells occur through pas-
sive demethylation. It is possible that memory B cells of
healthy controls undergo more divisions than HIGM2 pa-
tients, similarly to what has been described for Aicda–/–
mice (61). This could explain the partial impairment of pas-
sive demethylation in HIGM2 patients. For active changes,
no associations with AID targets were found. These find-
ings are also in line with those by Álvarez-Prado et al. (35),
which indicated that AID-mediated mutation frequencies
are too low. Such low frequency would be unlikely to pro-
duce a perceptible effect at the level of DNA methylation.
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leagues (13), it is remarkable that even without the removal
of PMDs in their analysis, the overlap between the DNA
methylation changes and AID-associated dsDNA breaks
was very small, which again reinforces the notion that AID
may not be directly involved in DNA demethylation events
of B cell maturation. A limitation of our analysis was the
lack of effective human models to study the direct contribu-
tion of AID activity to active demethylation. Therefore, we
cannot discard the possibility that the use of mouse models
may not be directly attributable to the functions of human
AID in the context of HIGM2. However, comparing Aicda-
/- mouse model with a mouse model deficient for BER and
MMR pathways (Ung-/- Msh2-/-), we were able to deduce
that DNA methylation during B cell maturation, at least in
mice, was not dependent on AID enzymatic activity. Fur-
thermore, there is a 92% identity between mouse and human
AID protein sequences, in which the catalytic and hotspot
recognition domains are conserved.
Another limitation of our analysis is that we work under
the assumption that all deaminase activity is attributed to
AID and that no other targets exist apart from AID off-
targets and Ig genes. Without further evidence, we cannot
effectively conclude that AID enzymatic activity is not es-
sential to mediate DNA demethylation during B cell mat-
uration. Moreover, AID hotspots were originally identified
as genomic locations of SHM (29), but further experiments
would be required to verify that they are direct targets of
AID deaminase activity in the context of human B cells.
A second major conclusion of our study concerns the
identification of DNA methylation defects in naı̈ve B cells
from HIGM2 patients in relation to healthy controls. Cus-
tomarily, AID expression has been regarded as being re-
stricted to GC B cells, but some evidence suggests that AID
may also have a role in central B cell tolerance (48,49,62).
Along this line, during B cell development, these cells not
only become activated in the GC but also in previous stages
of differentiation in the bone marrow, where self-reactive
immature B cells are activated in a process character-
ized by the upregulation of both AID and recombination-
activating gene 2 (RAG2) and the downregulation of the
anti-apoptotic MCL-1 (63). In this context, AID activity
increases the probability of genomic damage with the sub-
sequent activation of apoptosis through p53, which is also
enhanced by the inhibition of the anti-apoptotic proteins
BCL2 and MCL-1 (49). At this point, self-reactive imma-
ture B cells that are unable to correct their affinity for
self-antigens by receptor editing are eliminated. In patients
with AID deficiency, this mechanism of cell removal is im-
paired and autoreactive cells accumulate (49). Indeed, we
noted that HIGM2 patients accumulated more autoreac-
tive B cells than healthy donors, a finding that is compati-
ble with the previously described high frequency of autoim-
mune disorders in this type of patients (58). The failure in
AID function in these patients could be responsible for the
smaller degree of genomic damage that promotes the ex-
pansion of autoreactive naı̈ve B cells. These self-reactive B
cells, owing to the persistent activation of their BCR dur-
ing negative selection in the bone marrow, display a more
demethylated profile in genes downstream of the BCR com-
pared with non-autoreactive naı̈ve B cells. However, we have
only replicated this data in a selected number of CpGs and
cannot assume that the pre-activation of autoreactive naı̈ve
B cells in HIGM2 accounts for all the observed alterations
in genome-wide DNA methylation. It is possible that other
mechanisms may actively contribute to this phenomenon.
Our results, therefore, indicate that the enhanced demethy-
lation of BCR downstream targets in HIGM2 naı̈ve B cells
may be the result of the expansion of autoreactive B cell
clones as a consequence of the absence of AID. Further-
more, in order to generalize our findings to all variants of
HIGM2 it would be important to extend these analyses to
a bigger cohort of patients with different genetic mutations
of the AICDA gene (38), as they can have a different impact
on B cell function.
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Torroja,C., de Yébenes,V.G. and Ramiro,A.R. (2018) A broad atlas
of somatic hypermutation allows prediction of activation-induced
deaminase targets. J. Exp. Med., 215, 761–771.
36. Hansen,K.D., Sabunciyan,S., Langmead,B., Nagy,N., Curley,R.,
Klein,G., Klein,E., Salamon,D. and Feinberg,A.P. (2014) Large-scale
hypomethylated blocks associated with Epstein-Barr virus-induced
B-cell immortalization. Genome Res., 24, 177–184.
37. Garcia-Alonso,L., Iorio,F., Matchan,A., Fonseca,N., Jaaks,P.,
Peat,G., Pignatelli,M., Falcone,F., Benes,C.H., Dunham,I. et al.
(2018) Transcription factor activities enhance markers of drug
sensitivity in cancer. Cancer Res., 78, 769–780.
38. Durandy,A., Peron,S., Taubenheim,N. and Fischer,A. (2006)
Activation-induced cytidine deaminase: structure-function
relationship as based on the study of mutants. Hum. Mutat., 27,
1185–1191.
39. Hudson,T.J., Anderson,W., Aretz,A., Barker,A.D., Bell,C.,






/nar/article/49/9/5057/6266447 by guest on 25 June 2021
Nucleic Acids Research, 2021, Vol. 49, No. 9 5073
(2010) International network of cancer genome projects. Nature, 464,
993–998.
40. Zhou,W., Dinh,H.Q., Ramjan,Z., Weisenberger,D.J., Nicolet,C.M.,
Shen,H., Laird,P.W. and Berman,B.P. (2018) DNA methylation loss
in late-replicating domains is linked to mitotic cell division. Nat.
Genet., 50, 591–602.
41. Lister,R., Pelizzola,M., Dowen,R.H., Hawkins,R.D., Hon,G.,
Tonti-Filippini,J., Nery,J.R., Lee,L., Ye,Z., Ngo,Q.-M.M. et al.
(2009) Human DNA methylomes at base resolution show widespread
epigenomic differences. Nature, 462, 315–322.
42. Durek,P., Nordström,K., Gasparoni,G., Salhab,A., Kressler,C., de
Almeida,M., Bassler,K., Ulas,T., Schmidt,F., Xiong,J. et al. (2016)
Epigenomic profiling of human CD4+ T cells supports a linear
differentiation model and highlights molecular regulators of memory
development. Immunity, 45, 1148–1161.
43. Wu,X. and Zhang,Y. (2017) TET-mediated active DNA
demethylation: mechanism, function and beyond. Nat. Rev. Genet.,
18, 517–534.
44. Rogozin,I.B. and Kolchanov,N.A. (1992) Somatic hypermutagenesis
in immunoglobulin genes. II. Influence of neighbouring base
sequences on mutagenesis. BBA - Gene Struct. Expr., 171, 11–18.
45. Qian,J., Wang,Q., Dose,M., Pruett,N., Kieffer-Kwon,K.R., Resch,W.,
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